Compare BORR & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BORR | SVRA |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 995.8M | 1.1B |
| IPO Year | 2017 | 2009 |
| Metric | BORR | SVRA |
|---|---|---|
| Price | $3.44 | $4.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $4.93 | ★ $11.06 |
| AVG Volume (30 Days) | ★ 8.5M | 2.9M |
| Earning Date | 11-18-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.14 | $4,204.68 |
| P/E Ratio | $20.64 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.89 | $4.13 |
| 52 Week High | $6.66 | $7.01 |
| Indicator | BORR | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 43.43 | 50.47 |
| Support Level | $3.10 | $4.73 |
| Resistance Level | $4.64 | $5.40 |
| Average True Range (ATR) | 0.20 | 0.31 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 31.90 | 52.84 |
Borr Drilling Ltd is an offshore shallow-water drilling contractor providing services to the oil and gas industry. Its operations focus on the ownership, contracting, and operation of jack-up rigs in shallow-water areas, including the provision of related equipment and work crews to conduct oil and gas drilling and workover operations for exploration and production (E&P) customers. The company contracts its rigs on a dayrate basis to drill wells for integrated oil companies, state-owned national oil companies, and independent oil and gas companies. It operates in one reportable segment.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).